Founded in 2000, Metabometrix has developed unique analytical and data processing advancements in metabonomics over the past 25 years. Led by Professor Jeremy Nicholson, the Chief Scientist, the company specializes in characterizing biochemical changes caused by interventions and conditions, such as drug toxicity, clinical disease, therapeutic intervention, and nutrition. With a strong track record in completing successful projects for both industrial and academic clients, Metabometrix's expertise in metabonomics has significant potential in drug discovery, systems biology, and personalized medicine. Located in central London, the company utilizes advanced analytical technology and data processing tools to collaborate with clients in the pharmaceutical, biotechnology, and life science industries, focusing on predictive toxicology, disease biomarkers, clinical trial targeting, and disease risk assessment. Additionally, Metabometrix has been actively involved in large-scale consortia, including EC-funded projects, further solidifying its position as a key player in the field.